A software prototype for the assessment of tumor treatment response using diffusion and perfusion MR imaging

Advanced MRI techniques including diffusion and perfusion weighted imaging, has the potential to provide early surrogate biomarkers to detect, characterize and assess treatment response of tumors. However, the widely accepted Response Evaluation Criteria in Solid Tumors (RECIST) are still considered as the gold standard for the evaluation of treatment response in solid tumors, even if according to recent studies RECIST seem to disregard the extent of necrosis, which is the target of all effective locoregional therapies. This is partly due to the fact that measurements of tumor size aren't the best criterion for assessing actual early response. On the other hand, more sophisticated techniques such as the Apparent Diffusion Coefficient (ADC) and perfusion parameters are usually processed manually and evaluated independently using commercial CAD software, not widely available. In this paper we present an open access extensible software platform providing both diffusion and perfusion analysis in a single, user friendly environment that allows the radiologist to easily and objectively evaluate tumor response to therapy.

[1]  R. Gillies,et al.  Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. , 1999, Neoplasia.

[2]  A. Padhani,et al.  The RECIST criteria: implications for diagnostic radiologists , 2001 .

[3]  M. Décorps,et al.  Methodology of brain perfusion imaging , 2001, Journal of magnetic resonance imaging : JMRI.

[4]  R. Gillies,et al.  Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. , 2004, Neoplasia.

[5]  B. Ross,et al.  Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Vangelis Sakkalis,et al.  DoctorEye: A multifunctional open platform for fast annotation and visualization of tumors in medical images , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[7]  P. Choyke,et al.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.

[8]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[9]  Vangelis Sakkalis,et al.  Evaluation framework for the multilevel macroscopic models of solid tumor growth in the glioma case , 2010, 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology.

[10]  Vangelis Sakkalis,et al.  DoctorEye: A Clinically Driven Multifunctional Platform, for Accurate Processing of Tumors in Medical Images , 2010, The open medical informatics journal.

[11]  M. Schocke,et al.  ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma , 2011, Neuroradiology.

[12]  P. Cochat,et al.  Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[13]  Michalis E. Zervakis,et al.  High-Grade Glioma Diffusive Modeling Using Statistical Tissue Information and Diffusion Tensors Extracted from Atlases , 2012, IEEE Transactions on Information Technology in Biomedicine.

[14]  Michalis E. Zervakis,et al.  In-Depth Analysis and Evaluation of Diffusive Glioma Models , 2012, IEEE Transactions on Information Technology in Biomedicine.